MaxCyte Past Earnings Performance
Past criteria checks 0/6
MaxCyte's earnings have been declining at an average annual rate of -27.7%, while the Life Sciences industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 19.2% per year.
Key information
-27.7%
Earnings growth rate
-10.4%
EPS growth rate
| Life Sciences Industry Growth | 36.9% |
| Revenue growth rate | 19.2% |
| Return on equity | -16.3% |
| Net Margin | -91.8% |
| Next Earnings Update | 07 May 2024 |
Recent past performance updates
Recent updates
Downgrade: Here's How Analysts See MaxCyte, Inc. (LON:MXCT) Performing In The Near Term
Mar 14
Here's Why We're Not Too Worried About MaxCyte's (LON:MXCT) Cash Burn Situation
Mar 07Analysts Have Just Cut Their MaxCyte, Inc. (LON:MXCT) Revenue Estimates By 22%
Oct 07Here's Why We're Not Too Worried About MaxCyte's (LON:MXCT) Cash Burn Situation
Aug 12MaxCyte, Inc. (LON:MXCT) Analysts Just Slashed This Year's Revenue Estimates By 11%
May 15Investors Don't See Light At End Of MaxCyte, Inc.'s (LON:MXCT) Tunnel And Push Stock Down 28%
May 14We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth
Apr 27Companies Like MaxCyte (LON:MXCT) Are In A Position To Invest In Growth
Nov 20Here's Why We're Not Too Worried About MaxCyte's (LON:MXCT) Cash Burn Situation
Mar 02We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth
Nov 17We're Not Worried About MaxCyte's (LON:MXCT) Cash Burn
Jul 25MaxCyte (LON:MXCT) Shareholders Have Enjoyed A Whopping 545% Share Price Gain
Feb 22If You Had Bought MaxCyte (LON:MXCT) Shares A Year Ago You'd Have Earned 249% Returns
Nov 24
Revenue & Expenses BreakdownBeta
How MaxCyte makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 41 | -38 | 57 | 24 |
| 30 Sep 23 | 38 | -37 | 53 | 24 |
| 30 Jun 23 | 41 | -33 | 50 | 23 |
| 31 Mar 23 | 41 | -30 | 48 | 22 |
| 31 Dec 22 | 44 | -24 | 44 | 20 |
| 30 Sep 22 | 42 | -24 | 44 | 17 |
| 30 Jun 22 | 41 | -20 | 41 | 15 |
| 31 Mar 22 | 39 | -16 | 36 | 13 |
| 31 Dec 21 | 34 | -19 | 32 | 15 |
| 30 Sep 21 | 32 | -17 | 26 | 17 |
| 30 Jun 21 | 29 | -17 | 21 | 19 |
| 31 Mar 21 | 27 | -16 | 18 | 20 |
| 31 Dec 20 | 26 | -12 | 16 | 18 |
| 30 Sep 20 | 24 | -11 | 15 | 17 |
| 30 Jun 20 | 24 | -9 | 15 | 16 |
| 31 Mar 20 | 23 | -11 | 14 | 17 |
| 31 Dec 19 | 22 | -13 | 13 | 18 |
| 30 Sep 19 | 20 | -13 | 13 | 17 |
| 30 Jun 19 | 18 | -14 | 13 | 16 |
| 31 Mar 19 | 17 | -11 | 12 | 14 |
| 31 Dec 18 | 17 | -9 | 12 | 11 |
| 30 Sep 18 | 16 | -10 | 11 | 12 |
| 30 Jun 18 | 15 | -10 | 11 | 12 |
| 31 Mar 18 | 14 | -10 | 11 | 12 |
| 31 Dec 17 | 14 | -10 | 11 | 11 |
| 30 Sep 17 | 13 | -8 | 11 | 9 |
| 30 Jun 17 | 13 | -6 | 11 | 7 |
| 31 Mar 17 | 13 | -5 | 10 | 6 |
| 31 Dec 16 | 12 | -4 | 9 | 5 |
| 30 Sep 16 | 11 | -4 | 8 | 4 |
| 30 Jun 16 | 11 | -3 | 7 | 4 |
| 31 Mar 16 | 10 | -3 | 6 | 3 |
| 31 Dec 15 | 9 | -4 | 6 | 3 |
| 30 Sep 15 | 9 | -4 | 6 | 3 |
| 30 Jun 15 | 8 | -4 | 6 | 3 |
| 31 Mar 15 | 8 | -4 | 5 | 3 |
| 31 Dec 14 | 7 | -4 | 5 | 2 |
| 31 Dec 13 | 7 | -3 | 5 | 2 |
Quality Earnings: MXCT is currently unprofitable.
Growing Profit Margin: MXCT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MXCT is unprofitable, and losses have increased over the past 5 years at a rate of 27.7% per year.
Accelerating Growth: Unable to compare MXCT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MXCT is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (6.5%).
Return on Equity
High ROE: MXCT has a negative Return on Equity (-16.33%), as it is currently unprofitable.